Trial Profile

A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NOUS-209 (Primary) ; Pembrolizumab (Primary)
Indications Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Nouscom

Most Recent Events

20 Nov 2024 Planned End Date changed from 15 Jul 2026 to 30 Nov 2026.
20 Nov 2024 Planned primary completion date changed from 15 Mar 2025 to 30 Apr 2025.
19 Nov 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com